Literature DB >> 13362246

Requirements for persistent immunity to poliomyelitis.

J E SALK.   

Abstract

Entities:  

Keywords:  POLIOMYELITIS/immunology

Mesh：

Year:  1956        PMID： 13362246     DOI： 10.1097/00000441-195610000-00001

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN： 0002-9629            Impact factor:   2.378


× No keyword cloud information.
  10 in total

1.  Antibody response to Salk vaccine in Norwegian school children.

Authors:  J C ULSTRUP; R MEMMER
Journal:  Arch Gesamte Virusforsch       Date:  1959

2.  Prevalence of poliomyelitis neutralizing antibodies in Norwegian school children before vaccination.

Authors:  J C ULSTRUP; R MEMMER
Journal:  Arch Gesamte Virusforsch       Date:  1959

3.  [Results of an experimental vaccination against poliomyelitis].

Authors:  B MELEN; T WESSLEN; G OLIN
Journal:  Arch Gesamte Virusforsch       Date:  1959

4.  The antigenic activity of some poliomyelitis vaccines used in the United Kingdom in 1958.

Authors:  E J KENDALL; R L VOLLUM; T S BESWICK; A MILLER; J O TOBIN
Journal:  J Hyg (Lond)       Date:  1960-12

5.  Poliovirus antibody response after various vaccination schedules and at different ages.

Authors:  D R MACLEOD; C W ARMSTRONG; G W MOSS; F C POTTER; R J WILSON
Journal:  Can Med Assoc J       Date:  1959-09-15       Impact factor: 8.262

6.  Antibody responses to British poliomyelitis vaccine of children with naturally occurring antibody.

Authors:  K RUSSELL
Journal:  Br Med J       Date:  1958-03-15

7.  [Age factor of the sero-immunity of poliomyelitis viruses and ECHO virus type 9].

Authors:  R SAUTHOFF; E HANSERT; H K MITTELSTRASS
Journal:  Klin Wochenschr       Date:  1958-04-15

8.  Poliomyelitis vaccination in the fall of 1956.

Authors:  J E SALK
Journal:  Am J Public Health Nations Health       Date:  1957-01

9.  Living Poliomyelitis Vaccine.

Authors: 
Journal:  Can Med Assoc J       Date:  1957-02-15       Impact factor: 8.262

10.  Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs).

Authors:  Radboud J Duintjer Tebbens; Mark A Pallansch; Jong-Hoon Kim; Cara C Burns; Olen M Kew; M Steven Oberste; Ousmane M Diop; Steven G F Wassilak; Stephen L Cochi; Kimberly M Thompson
Journal:  Risk Anal       Date:  2013-03-07       Impact factor: 4.000
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.